# Coenzyme Q10 and Pyridoxal Phosphate Deficiency Is a Mucopolysaccharidosis Type III

JIMD Reports

25, 1-7

DOI: 10.1007/8904_2015_421

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Secondary coenzyme Q 10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders. Mitochondrion, 2016, 30, 51-58. | 1.6 | 70 |
| 2 | Molecular diagnosis of coenzyme Q<sub>10</sub> deficiency: an update. Expert Review of Molecular Diagnostics, 2018, 18, 491-498. | 1.5 | 33 |
| 3 | Plasma coenzyme Q10 status is impaired in selected genetic conditions. Scientific Reports, 2019, 9, 793. | 1.6 | 27 |
| 4 | Putative adjunct therapies to target mitochondrial dysfunction and oxidative stress in phenylketonuria, lysosomal storage disorders and peroxisomal disorders. Expert Opinion on Orphan Drugs, 2020, 8, 431-444. | 0.5 | 0 |
| 5 | Oxidative Stress in Mucopolysaccharidoses: Pharmacological Implications. Molecules, 2021, 26, 5616. | 1.7 | 12 |
| 6 | The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy. Frontiers in Pharmacology, 2022, 13, . | 1.6 | 10 |
| 7 | Coenzyme Q10: Role in Less Common Age-Related Disorders. Antioxidants, 2022, 11, 2293. | 2.2 | 1 |
| 8 | Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets. International Journal of Molecular Sciences, 2023, 24, 477. | 1.8 | 13 |